Nicholas C. Harbist to Speak at ACI's 13th Annual Forum on Fraud and Abuse in the Sale and Marketing of Drug
Blank Rome Partner Nicholas C. Harbist will be speaking at the American Conference Institute's (ACI) 13th Annual Forum on Fraud and Abuse in the Sale and Marketing of Drugs on March 21, 2013 at ONE UN New York in New York City.
Mr. Harbist's panel, "Steering Clear of Civil and Criminal Liability When Conducting Clinical Trials," will cover topics such as pinpointing common clinical trials practices that may raise a red flag for enforcers; exploring prosecutorial tools to pursue False Claims Act (FCA) liability for wrongful conduct in connection with a trial; preparing for the certain prospect of increased monitoring and OIG oversight for clinical trials conducted globally; factoring compliance into your clinical trial's design; and factoring clinical trials into your compliance program's design.
The Forum will be held over a course of three days (March 20-22) and will also offer a number of other sessions discussing identifying specific sales and marketing practices that may raise red flags, guarding proactively against impermissible off-label promotions, revamping compliance programs in light of recent FCA investigations into alleged GMP violations, and minimizing global anti-bribery risks and Foreign Corrupt Practice Act (FCPA) violations when managing a global sales and marketing force, to name a few.
ACI is an organization devoted to providing senior decision-makers with the business intelligence they need to respond to both domestic and international challenges. Operating as a think tank staffed by industry specialists, lawyers, and other professionals, ACI monitors trends and developments in all major industry sectors, the law, and public policy.
Event details can be found online at www.americanconference.com/fadrugs.